Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans
(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders. The AIM-traded firm said that would allow it to fulfil critical payments and continue exploring short- and long-term financing solutions.
It said the obtained funding would address immediate short-term financing requirements until the end of March, supplementing its current cash reserves of about €4.3m as of 19 February.
Faron said it was seeking an additional €5m in short-term bridge financing to ensure financial stability and facilitate the publishing of its annual accounts for 2023 on 13 March.
In response to breaching certain undertakings outlined in the secured debt agreement with IPF Fund II SCA, SICAV-FIAR, Faron said it was facing account restrictions.
However, the binding commitments for convertible loans had enabled it to make essential payments and secure a waiver for certain events of default under the terms of the facilities agreement.
The waiver also included amendments to the fee structure and the issue of special rights to IPF, allowing it to subscribe for new ordinary shares.
Looking ahead, Faron said it was actively pursuing both short- and longer-term financing options.
The board said it intended to propose a larger share issue at the annual general meeting on 5 April.
That proposed offering aimed to secure funding for 2024, particularly for the continuation of the BEXMAB study, with a targeted size to meet the company's cash runway needs.
"This fundraise will enable us to meet our immediate financing needs and continue our ambitious bexmarilimab development programme, with a focus on delivering next milestones," said chief executive officer Dr Markku Jalkanen.
"These funds are part of the larger financing plan to secure cash runway for 2024 and to complete phase two study and receive FDA's guidance for the pivotal study part.
"We would like to thank support from our investors in developing this novel immunotherapy, especially for myeloid leukaemia with very few treatment options."
To further support short-term financing, Dr Jalkanen had voluntarily agreed to forgo his salary for the next three months.
The company said it would provide updates on the BEXMAB phase one readout in mid-March, focusing on the efficacy of bexmarilimab on HMA-failed MDS patients, with plans to seek a total of €35m to complete the ongoing phase two study and obtain regulatory feedback from the FDA.
At 1018 GMT, shares in Faron Pharmaceuticals were up 3.61% at 158p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.